Changchun Bcht Biotechnology Wins Acceptance for RSV Antibody Trial Application

Stock News

Sep 22

Changchun Bcht Biotechnology Co. (SH: 688276) has announced that it recently received the Acceptance Notice from the National Medical Products Administration regarding the clinical trial application for its recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation, referred to as the RSV antibody.

The RSV antibody accepted for review is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies have demonstrated that the product exhibits strong efficacy; preclinical toxicology studies indicate that the product is generally well tolerated, safe, and controllable.

Additionally, the product enables a single-dose administration to cover a complete RSV epidemic season, thereby enhancing patient medication adherence and the convenience of prevention.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg1.tigeractivity.com/news/1192668896"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1192668896\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1192668896?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-22 19:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1192668896","market":"other","top_or_hot":-1,"title":"Changchun Bcht Biotechnology Wins Acceptance for RSV Antibody Trial Application","media":"Stock News","content":"<p><b>Changchun Bcht Biotechnology Co.</b> (SH: 688276) has announced that it recently received the Acceptance Notice from the National Medical Products Administration regarding the clinical trial application for its recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation, referred to as the RSV antibody.<br><br>The RSV antibody accepted for review is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies have demonstrated that the product exhibits strong efficacy; preclinical toxicology studies indicate that the product is generally well tolerated, safe, and controllable.<br><br>Additionally, the product enables a single-dose administration to cover a complete RSV epidemic season, thereby enhancing patient medication adherence and the convenience of prevention.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Changchun Bcht Biotechnology Wins Acceptance for RSV Antibody Trial Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChangchun Bcht Biotechnology Wins Acceptance for RSV Antibody Trial Application\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-22 19:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Changchun Bcht Biotechnology Co.</b> (SH: 688276) has announced that it recently received the Acceptance Notice from the National Medical Products Administration regarding the clinical trial application for its recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation, referred to as the RSV antibody.<br><br>The RSV antibody accepted for review is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies have demonstrated that the product exhibits strong efficacy; preclinical toxicology studies indicate that the product is generally well tolerated, safe, and controllable.<br><br>Additionally, the product enables a single-dose administration to cover a complete RSV epidemic season, thereby enhancing patient medication adherence and the convenience of prevention.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMED","symbol_name":"iShares Health Innovation Active ETF","start_time":0,"source_url":"","article_id":"1192668896","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1192668896","pubTimestamp":1790076019,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Changchun Bcht Biotechnology Co. (SH: 688276) has announced that it recently received the Acceptance Notice from the National Medical Products Administration regarding the clinical trial application...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688276":"百克生物","BMED":"iShares Health Innovation Active ETF","PSYK":"PSYK ETF","IBBQ":"Invesco Nasdaq Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BK0239":"医药制造"},"translate_title":"长春Bcht生物科技RSV抗体试验申请获受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688276":1,"BMED":1,"MDTX":1,"IBBQ":1,"PSYK":1,"IBBJ":1},"content_text":"Changchun Bcht Biotechnology Co. (SH: 688276) has announced that it recently received the Acceptance Notice from the National Medical Products Administration regarding the clinical trial application for its recombinant human anti-respiratory syncytial virus monoclonal antibody injection combination preparation, referred to as the RSV antibody.The RSV antibody accepted for review is intended to prevent lower respiratory tract infections caused by RSV in newborns and infants. Preclinical in vivo and in vitro pharmacodynamic studies have demonstrated that the product exhibits strong efficacy; preclinical toxicology studies indicate that the product is generally well tolerated, safe, and controllable.Additionally, the product enables a single-dose administration to cover a complete RSV epidemic season, thereby enhancing patient medication adherence and the convenience of prevention.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}